A Phase 2A, Randomized, Blinded, Placebo and Active Controlled, 2 Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia.

Trial Profile

A Phase 2A, Randomized, Blinded, Placebo and Active Controlled, 2 Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs ADL 5747 (Primary) ; Pregabalin
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Adolor Corporation
  • Most Recent Events

    • 07 Jul 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 07 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top